PDCD1 and neoplasm: While thymic expression of RANKL and RANK and the potential role for this pathway in negative selection may contribute to some aspects of combination efficacy of RANK/RANKL antagonism with ICI,16, 24 the observed distribution of RANK and RANKL within the TME more likely informs the distinct mechanisms by which the anti‐RANKL/PD‐1 BsAb evokes superior anti‐tumor immunity and efficacy.